Novel eye drug targets $10 billion market

23 January 2020

Ocuphire Pharma has picked up an exclusive, global sublicence from Apexian Pharmaceuticals for the firm’s Ref-1 Inhibitor program, including lead candidate APX3330.

Ocuphire, which is focused on ophthalmic disorders, will gain rights for all ophthalmic and diabetic indications. Financial terms were not disclosed.

APX3330 is a first-in-class oral small molecule that selectively targets and inhibits the Ref-1 protein. The firm hopes that APX3330 could improve eye health in diabetics.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK